In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck’s Keytruda (pembrolizumab). With a nearly ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck's Keytruda (pembrolizumab ... Thus these two ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...